title: Micro-RNAs and High-Density Lipoprotein Metabolism.
abstract: Improved prevention and treatment of cardiovascular diseases is one of the challenges in Western societies, where ischemic heart disease and stroke are the leading cause of death. Early epidemiological studies have shown an inverse correlation between circulating high-density lipoprotein-cholesterol (HDL-C) and cardiovascular diseases. The cardioprotective effect of HDL is because of its ability to remove cholesterol from plaques in the artery wall to the liver for excretion by a process known as reverse cholesterol transport. Numerous studies have reported the role that micro-RNAs (miRNA) play in the regulation of the different steps in reverse cholesterol transport, including HDL biogenesis, cholesterol efflux, and cholesterol uptake in the liver and bile acid synthesis and secretion. Because of their ability to control different aspects of HDL metabolism and function, miRNAs have emerged as potential therapeutic targets to combat cardiovascular diseases. In this review, we summarize the recent advances in the miRNA-mediated control of HDL metabolism. We also discuss how HDL particles serve as carriers of miRNAs and the potential use of HDL-containing miRNAs as cardiovascular diseases biomarkers.
authors.affiliation: From the Vascular Biology and Therapeutics Program (A.C.-D., L.G., Y.S., C.F.-H.) and Integrative Cell Signaling and Neurobiology of Metabolism Program, Section of Comparative Medicine and Department of Pathology (A.C.-D., L.G., Y.S., C.F.-H.), Yale University School of Medicine, New Haven, CT; and Division of Cardiology, Department of Medicine, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan (C.-S.L.).
authors.forename: Alberto
authors.initials: A
authors.lastname: Canfrán-Duque
authors.affiliation: From the Vascular Biology and Therapeutics Program (A.C.-D., L.G., Y.S., C.F.-H.) and Integrative Cell Signaling and Neurobiology of Metabolism Program, Section of Comparative Medicine and Department of Pathology (A.C.-D., L.G., Y.S., C.F.-H.), Yale University School of Medicine, New Haven, CT; and Division of Cardiology, Department of Medicine, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan (C.-S.L.).
authors.forename: Chin-Sheng
authors.initials: CS
authors.lastname: Lin
authors.affiliation: From the Vascular Biology and Therapeutics Program (A.C.-D., L.G., Y.S., C.F.-H.) and Integrative Cell Signaling and Neurobiology of Metabolism Program, Section of Comparative Medicine and Department of Pathology (A.C.-D., L.G., Y.S., C.F.-H.), Yale University School of Medicine, New Haven, CT; and Division of Cardiology, Department of Medicine, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan (C.-S.L.).
authors.forename: Leigh
authors.initials: L
authors.lastname: Goedeke
authors.affiliation: From the Vascular Biology and Therapeutics Program (A.C.-D., L.G., Y.S., C.F.-H.) and Integrative Cell Signaling and Neurobiology of Metabolism Program, Section of Comparative Medicine and Department of Pathology (A.C.-D., L.G., Y.S., C.F.-H.), Yale University School of Medicine, New Haven, CT; and Division of Cardiology, Department of Medicine, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan (C.-S.L.).
authors.forename: Yajaira
authors.initials: Y
authors.lastname: Suárez
authors.affiliation: From the Vascular Biology and Therapeutics Program (A.C.-D., L.G., Y.S., C.F.-H.) and Integrative Cell Signaling and Neurobiology of Metabolism Program, Section of Comparative Medicine and Department of Pathology (A.C.-D., L.G., Y.S., C.F.-H.), Yale University School of Medicine, New Haven, CT; and Division of Cardiology, Department of Medicine, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan (C.-S.L.). carlos.fernandez@yale.edu.
authors.forename: Carlos
authors.initials: C
authors.lastname: Fernández-Hernando
mesh_terms: D000818:Animals; D001692:Biological Transport; D002318:Cardiovascular Diseases / Q000097:blood / Q000175:diagnosis / Q000378:metabolism* / Q000517:prevention & control; D050171:Dyslipidemias / Q000097:blood / Q000235:genetics / Q000378:metabolism* / Q000628:therapy; D005786:Gene Expression Regulation; D005819:Genetic Markers; D006801:Humans; D008075:Lipoproteins, HDL / Q000097:blood / Q000235:genetics / Q000378:metabolism*; D035683:MicroRNAs / Q000097:blood / Q000235:genetics / Q000378:metabolism*; D011237:Predictive Value of Tests; D011379:Prognosis
chemical_list: D005819:Genetic Markers; D008075:Lipoproteins, HDL; C550416:MIRN33a microRNA, human; D035683:MicroRNAs
keywords: atherosclerosis; biomarkers; cardiovascular diseases; cholesterol, HDL; microRNAs